CCR5 antagonists useful for treating aids

Compounds of the formula ##STR1##

or a pharmaceutically acceptable salt or isomer thereof, wherein:

• Q, X and Z are CH or N;
• R, R⁴-R⁷ and R¹³ are H or alkyl;
• R¹ is H, alkyl, fluoroalkyl, R⁹-arylalkyl, R⁹-heteroarylalkyl, alkyl-SO₂, cycloalkyl-SO₂, fluoroalkyl-SO₂, R⁹-aryl-SO₂, R⁹-heteroaryl-SO₂, N(R²²)(R²³)SO₂, alkyl-C(O), cycloalkyl-C(O), fluoroalkyl-C(O), R⁹-aryl-C(O), NH-alkyl-C(O) or R⁹-aryl-NHC(O);
• R² is H and R³ is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R⁹-aryl, R⁹-arylalkyl, R⁹-heteroaryl, or R⁹-heteroarylalkyl, and when X and Z are each CH, R³ is alkoxy, R⁹-aryloxy, R⁹-heteroaryloxy, alkylC(O)O, alkylaminoC(O)O, alkylC(O)NR¹³, alkylOC(O)NR¹³ or alkylaminoC(O)NR¹³;
• or R² and R³ together are O, NOR¹⁰, NNR¹¹R¹² or CH-alkyl;
• R⁸ is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl;
• R⁹-R¹² are as defined;

  are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.